Capricor Therapeutics price target raised to $30 from $25 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Capricor Therapeutics (CAPR) to $30 from $25 and keeps an Overweight rating on the shares. Capricor’s Q3 earnings report didn’t contain any major surprises, though the team added some color on the potential regulatory and commercial path, the analyst tells investors in a research note. Capricor has been a top inbound call name, with a lot of new investors to the story surprised by the relatively high royalties that the company has guided to receive from its partnership, and Cantor thinks Capricor could annualize about $1B in peak revenues in the U.S. alone.